Affimed Announces Receipt of Nasdaq Delisting Notice
Affimed Announces Filing for the Opening of Insolvency Proceedings
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Affimed Appoints New CEO, Shares Fall on Leadership Change
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed Announces Annual General Meeting of Shareholders
7 Penny Biotech Stocks to Triple Your Investment
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed Reports 2023 Financial Results and Operational Progress
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
Why Is Affimed (AFMD) Stock Moving Today?
7 of the Best Speculative Stocks You Can Snag for Less Than $1
Affimed Announces 1-for-10 Reverse Stock Split
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
Affimed Announces Leadership Change and Organizational Restructuring
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
3 Penny Stocks That Are Too Compelling to Ignore